DOCSLIB.ORG

Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule Revised: 04/06/2016 January - 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule Revised: 04/06/2016 January - 2016 Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule Revised: 04/06/2016 January - 2016 Code Short Description Modifier Age Range Non Fac Fee Fac Fee Effective Date** 0054T Bone Srgry Cmptr Fluor Image NA $84.39 0055T Bone Srgry Cmptr Ct/Mri Imag NA $84.39 0178T 64 Lead Ecg W/I&R M M 0179T 64 Lead Ecg W/Tracing M M 0180T 64 Lead Ecg W/I&R Only M M 0190T Place Intraoc Radiation Src M M 0191T Insert Ant Segment Drain Int $379.27 $379.27 0195T Prescrl Fuse W/O Instr L5/S1 NA M 0196T Prescrl Fuse W/O Instr L4/L5 NA M 0198T Ocular Blood Flow Measure M M 0200T Perq Sacral Augmt Unilat Inj $987.92 $243.46 0201T Perq Sacral Augmt Bilat Inj $553.69 $120.64 0202T Post Vert Arthrplst 1 Lumbar $4,128.40 $288.24 0205T Inirs Each Vessel Add-On NA $63.19 0206T Cptr Dbs Alys Car Elec Dta $14.66 $14.66 0207T Clear Eyelid Gland W/Heat $136.47 $68.53 0208T Audiometry Air Only $17.43 NA 0209T Audiometry Air & Bone $20.80 NA 0210T Speech Audiometry Threshold $13.07 NA 0211T Speech Audiom Thresh & Recog $20.80 NA 0212T Compre Audiometry Evaluation $21.00 $18.42 0213T Njx Paravert W/Us Cer/Thor $107.57 $60.82 0214T Njx Paravert W/Us Cer/Thor $53.09 $34.47 0215T Njx Paravert W/Us Cer/Thor $53.29 $34.87 0216T Njx Paravert W/Us Lumb/Sac $97.66 $52.10 0217T Njx Paravert W/Us Lumb/Sac $48.93 $29.72 0218T Njx Paravert W/Us Lumb/Sac $49.13 $30.11 0219T Plmt Post Facet Implt Cerv $238.91 $129.56 0220T Plmt Post Facet Implt Thor $238.91 $129.56 0221T Plmt Post Facet Implt Lumb $236.14 $127.77 0222T Plmt Post Facet Implt Addl $97.66 $34.27 0228T Us Tfrml Edrl Inj Crv/T 1lvl M M 0229T Njx Tfrml Eprl W/Us Cer/Thor M M 0230T Us Tfrml Edrl Inj L/S 1 Lvl M M 0231T Njx Tfrml Eprl W/Us Lumb/Sac M M 0232T Njx Platelet Plasma M M 0234T Trluml Perip Athrc Renal Art M M 0235T Trluml Perip Athrc Visceral NA M 0236T Trluml Perip Athrc Abd Aorta M M 0237T Trluml Perip Athrc Brchiocph M M 0238T Trluml Perip Athrc Iliac Art M M 0249T Ligation Hemorrhoid W/Us M M 0253T Insert Aqueous Drain Device M M 0254T Evasc Rpr Iliac Art Bifur NA M **Effective Date will only be populated when the rate begins after the published fee schedule date Page 1 of 243 Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule Revised: 04/06/2016 January - 2016 Code Short Description Modifier Age Range Non Fac Fee Fac Fee Effective Date** 0255T Evasc Rpr Iliac Art Bifr S&I 26 M M 10021 Fna W/O Image $69.14 $39.62 10022 Fna W/Image $79.24 $37.24 10030 Guide Cathet Fluid Drainage $438.59 $96.47 10035 Perq Dev Soft Tiss 1st Imag $300.72 $49.53 10036 Perq Dev Soft Tiss Add Imag $261.49 $24.96 10040 Acne Surgery $57.05 $49.72 10060 Drainage Of Skin Abscess $65.77 $54.68 10061 Drainage Of Skin Abscess $115.89 $101.43 10080 Drainage Of Pilonidal Cyst $100.63 $58.04 10081 Drainage Of Pilonidal Cyst $150.75 $96.08 10120 Remove Foreign Body $85.18 $58.44 10121 Remove Foreign Body $153.92 $105.19 10140 Drainage Of Hematoma/Fluid $91.52 $66.96 10160 Puncture Drainage Of Lesion $73.10 $54.28 10180 Complex Drainage Wound $138.87 $101.63 11000 Debride Infected Skin $30.51 $16.24 11001 Debride Infected Skin Add-On $12.08 $8.12 11004 Debride Genitalia & Perineum NA $332.02 11005 Debride Abdom Wall NA $449.49 11006 Debride Genit/Per/Abdom Wall NA $402.94 11008 Remove Mesh From Abd Wall NA $158.08 11010 Debride Skin At Fx Site $277.14 $159.27 11011 Debride Skin Musc At Fx Site $301.31 $170.76 11012 Deb Skin Bone At Fx Site $402.54 $243.86 11042 Deb Subq Tissue 20 Sq Cm/< $65.37 $35.06 11043 Deb Musc/Fascia 20 Sq Cm/< $128.57 $88.55 11044 Deb Bone 20 Sq Cm/< $177.50 $131.93 11045 Deb Subq Tissue Add-On $22.98 $14.86 11046 Deb Musc/Fascia Add-On $41.40 $31.89 11047 Deb Bone Add-On $70.13 $56.85 11055 Trim Skin Lesion $26.55 $9.11 11056 Trim Skin Lesions 2 To 4 $32.49 $12.88 11057 Trim Skin Lesions Over 4 $36.65 $16.84 11100 Biopsy Skin Lesion $57.85 $27.73 11101 Biopsy Skin Add-On $18.42 $14.26 11200 Removal Of Skin Tags <W/15 $49.33 $41.40 11201 Remove Skin Tags Add-On $10.70 $9.51 11300 Shave Skin Lesion 0.5 Cm/< $54.28 $20.01 11301 Shave Skin Lesion 0.6-1.0 Cm $66.96 $30.51 11302 Shave Skin Lesion 1.1-2.0 Cm $78.84 $35.86 11303 Shave Skin Lesion >2.0 Cm $87.16 $42.39 11305 Shave Skin Lesion 0.5 Cm/< $55.47 $22.39 11306 Shave Skin Lesion 0.6-1.0 Cm $68.15 $29.52 **Effective Date will only be populated when the rate begins after the published fee schedule date Page 2 of 243 Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule Revised: 04/06/2016 January - 2016 Code Short Description Modifier Age Range Non Fac Fee Fac Fee Effective Date** 11307 Shave Skin Lesion 1.1-2.0 Cm $80.43 $38.04 11308 Shave Skin Lesion >2.0 Cm $84.39 $42.00 11310 Shave Skin Lesion 0.5 Cm/< $63.39 $26.94 11311 Shave Skin Lesion 0.6-1.0 Cm $62.40 $37.44 11312 Shave Skin Lesion 1.1-2.0 Cm $89.74 $44.57 11313 Shave Skin Lesion >2.0 Cm $104.00 $57.25 11400 Exc Tr-Ext B9+Marg 0.5 Cm< $69.34 $45.36 11401 Exc Tr-Ext B9+Marg 0.6-1 Cm $83.40 $58.64 11402 Exc Tr-Ext B9+Marg 1.1-2 Cm $92.71 $64.58 11403 Exc Tr-Ext B9+Marg 2.1-3cm/< $107.57 $83.60 11404 Exc Tr-Ext B9+Marg 3.1-4 Cm $122.23 $92.12 11406 Exc Tr-Ext B9+Marg >4.0 Cm $176.31 $140.25 11420 Exc H-F-Nk-Sp B9+Marg 0.5/< $68.54 $46.16 11421 Exc H-F-Nk-Sp B9+Marg 0.6-1 $87.76 $62.20 11422 Exc H-F-Nk-Sp B9+Marg 1.1-2 $98.26 $76.66 11423 Exc H-F-Nk-Sp B9+Marg 2.1-3 $113.31 $89.15 11424 Exc H-F-Nk-Sp B9+Marg 3.1-4 $131.14 $102.02 11426 Exc H-F-Nk-Sp B9+Marg >4 Cm $187.60 $156.30 11440 Exc Face-Mm B9+Marg 0.5 Cm/< $75.48 $58.24 11441 Exc Face-Mm B9+Marg 0.6-1 Cm $94.10 $74.49 11442 Exc Face-Mm B9+Marg 1.1-2 Cm $105.39 $82.41 11443 Exc Face-Mm B9+Marg 2.1-3 Cm $125.79 $101.23 11444 Exc Face-Mm B9+Marg 3.1-4 Cm $158.08 $128.96 11446 Exc Face-Mm B9+Marg >4 Cm $219.69 $185.03 11450 Removal Sweat Gland Lesion $214.15 $143.23 11451 Removal Sweat Gland Lesion $272.98 $184.63 11462 Removal Sweat Gland Lesion $209.00 $136.69 11463 Removal Sweat Gland Lesion $276.15 $185.22 11470 Removal Sweat Gland Lesion $232.37 $159.87 11471 Removal Sweat Gland Lesion $286.85 $198.50 11600 Exc Tr-Ext Mal+Marg 0.5 Cm/< $107.77 $67.55 11601 Exc Tr-Ext Mal+Marg 0.6-1 Cm $128.17 $84.59 11602 Exc Tr-Ext Mal+Marg 1.1-2 Cm $139.07 $92.91 11603 Exc Tr-Ext Mal+Marg 2.1-3 Cm $159.07 $111.33 11604 Exc Tr-Ext Mal+Marg 3.1-4 Cm $176.90 $122.62 11606 Exc Tr-Ext Mal+Marg >4 Cm $253.57 $182.65 11620 Exc H-F-Nk-Sp Mal+Marg 0.5/< $108.96 $68.54 11621 Exc S/N/H/F/G Mal+Mrg 0.6-1 $128.96 $85.38 11622 Exc S/N/H/F/G Mal+Mrg 1.1-2 $143.82 $97.66 11623 Exc S/N/H/F/G Mal+Mrg 2.1-3 $168.98 $121.04 11624 Exc S/N/H/F/G Mal+Mrg 3.1-4 $190.57 $137.09 11626 Exc S/N/H/F/G Mal+Mrg >4 Cm $229.80 $168.19 11640 Exc F/E/E/N/L Mal+Mrg 0.5cm< $112.32 $70.92 11641 Exc F/E/E/N/L Mal+Mrg 0.6-1 $133.52 $88.95 **Effective Date will only be populated when the rate begins after the published fee schedule date Page 3 of 243 Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule Revised: 04/06/2016 January - 2016 Code Short Description Modifier Age Range Non Fac Fee Fac Fee Effective Date** 11642 Exc F/E/E/N/L Mal+Mrg 1.1-2 $152.54 $104.99 11643 Exc F/E/E/N/L Mal+Mrg 2.1-3 $179.87 $131.34 11644 Exc F/E/E/N/L Mal+Mrg 3.1-4 $221.87 $162.64 11646 Exc F/E/E/N/L Mal+Mrg >4 Cm $290.22 $226.03 11720 Debride Nail 1-5 $18.03 $8.32 11721 Debride Nail 6 Or More $25.16 $14.07 11730 Removal Of Nail Plate $55.47 $28.92 11732 Remove Nail Plate Add-On $20.01 $11.49 11740 Drain Blood From Under Nail $27.73 $18.42 11750 Removal Of Nail Bed $101.23 $79.44 11752 Remove Nail Bed/Tip $182.25 $148.77 11755 Biopsy Nail Unit $74.88 $44.18 11760 Repair Of Nail Bed $108.96 $66.17 11762 Reconstruction Of Nail Bed $157.29 $104.20 11765 Excision Of Nail Fold Toe $93.70 $53.09 11770 Remove Pilonidal Cyst Simple $156.30 $105.39 11771 Remove Pilonidal Cyst Exten $323.10 $247.03 11772 Remove Pilonidal Cyst Compl $391.84 $327.66 11900 Inject Skin Lesions </W 7 $31.10 $17.83 11901 Inject Skin Lesions >7 $39.22 $27.54 11920 Correct Skin Color 6.0 Cm/< $95.29 $64.58 11921 Correct Skn Color 6.1-20.0cm $111.13 $76.47 11922 Correct Skin Color Ea 20.0cm $34.47 $16.84 11950 Tx Contour Defects 1 Cc/< $41.20 $28.92 11951 Tx Contour Defects 1.1-5.0cc $54.68 $40.81 11952 Tx Contour Defects 5.1-10cc $73.50 $55.07 11954 Tx Contour Defects >10.0 Cc $88.55 $65.17 11960 Insert Tissue Expander(S) NA $535.86 11970 Replace Tissue Expander NA $345.49 11971 Remove Tissue Expander(S) $263.47 $180.47 11976 Remove Contraceptive Capsule $80.03 $53.29 11980 Implant Hormone Pellet(S) $52.69 $31.89 11981 Insert Drug Implant Device $78.84 $46.95 11982 Remove Drug Implant Device $89.54 $57.05 11983 Remove/Insert Drug Implant $125.00 $98.85 12001 Rpr S/N/Ax/Gen/Trnk 2.5cm/< $49.92 $25.16 12002 Rpr S/N/Ax/Gen/Trnk2.6-7.5cm $60.82 $33.08 12004 Rpr S/N/Ax/Gen/Trk7.6-12.5cm $71.71 $41.40 12005 Rpr S/N/A/Gen/Trk12.6-20.0cm $90.53 $53.88 12006 Rpr S/N/A/Gen/Trk20.1-30.0cm $107.37 $66.17 12007 Rpr S/N/Ax/Gen/Trnk >30.0 Cm $125.40 $83.60 12011 Rpr F/E/E/N/L/M 2.5 Cm/< $61.21 $31.30 12013 Rpr F/E/E/N/L/M 2.6-5.0 Cm $63.99 $32.88 12014 Rpr F/E/E/N/L/M 5.1-7.5 Cm $74.88 $42.39 **Effective Date will only be populated when the rate begins after the published fee schedule date Page 4 of 243 Michigan Department of Health and Human Services Practitioner and Medical Clinic Fee Schedule Revised: 04/06/2016 January - 2016 Code Short Description Modifier Age Range Non Fac Fee Fac Fee Effective Date** 12015 Rpr F/E/E/N/L/M 7.6-12.5 Cm $90.73 $53.29 12016 Rpr Fe/E/En/L/M 12.6-20.0 Cm $115.29 $72.90 12017
Load more

Recommended publications
  • The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
    The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands Clare Louise Wishart Submitted in accordance with the requirements for the degree of Doctor of Philosophy of Science University of Leeds School of Biomedical Sciences Faculty of Biological Sciences September 2013 I Intellectual Property and Publication Statements The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Clare Louise Wishart to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2013 The University of Leeds and Clare Louise Wishart. II Acknowledgments Firstly I would like to offer my sincerest thanks and gratitude to my supervisor, Dr. Dan Donnelly, who has been nothing but encouraging and engaging from day one. I have thoroughly enjoyed every moment of working alongside him and learning from his guidance and wisdom. My thanks go to my academic assessor Professor Paul Milner whom I have known for several years, and during my time at the University of Leeds he has offered me invaluable advice and inspiration. Additionally I would like to thank my academic project advisor Dr. Michael Harrison for his friendship, help and advice. I would like to thank Dr. Rosalind Mann and Dr. Elsayed Nasr for welcoming me into the lab as a new PhD student and sharing their experimental techniques with me, these techniques have helped me no end in my time as a research student.
    [Show full text]
  • List of Approved Ndas for Biological Products That Were Deemed to Be Blas on March 23, 2020
    List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 On March 23, 2020, an approved application for a biological product under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) was deemed to be a license for the biological product under section 351 of the Public Health Service Act (PHS Act) (see section 7002(e)(4)(A) of the Biologics Price Competition and Innovation Act of 2009). To enhance transparency and facilitate planning for the March 23, 2020, transition date, FDA compiled a preliminary list of approved applications for biological products under the FD&C Act that were listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) and that would be affected by this transition provision. FDA posted this list on the FDA website in December 2018, and periodically updated this list before the March 23, 2020, transition date. The September 2019 update to this preliminary list added certain administratively closed applications related to approved applications for biological products that were on the December 2018 version of this list. The January 2020 update to the preliminary list reflected a change to the definition of “biological product” made by the Further Consolidated Appropriations Act, 2020, which was enacted on December 20, 2019. Section 605 of this Act further amended the definition of a “biological product” in section 351(i) of the PHS Act to remove the parenthetical “(except any chemically synthesized polypeptide)” from the statutory category of “protein.” FDA has provided below a list of each approved application for a biological product under the FD&C Act that was deemed to be a license (i.e., an approved biologics license application (BLA)) for the biological product on March 23, 2020.
    [Show full text]
  • Corticorelin Acetate, a Synthetic Corticotropin-Releasing Factor with Preclinical Antitumor Activity, Alone and with Bevacizumab, Against Human Brain Tumor Models
    ANTICANCER RESEARCH 30: 5037-5042 (2010) Corticorelin Acetate, a Synthetic Corticotropin-releasing Factor with Preclinical Antitumor Activity, alone and with Bevacizumab, against Human Brain Tumor Models IDOIA GAMEZ1, ROBERT P. RYAN1 and STEPHEN T. KEIR2 1Celtic Pharmaceutical Development Services America, Inc., New York, NY 10022, U.S.A.; 2The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, NC 27710, U.S.A. Abstract. Background: Corticorelin acetate (CrA) is a brain tumors. The cause of PBE is believed to result in part synthetic form of corticotropin-releasing factor that is from the leakage of edematous brain tumor fluid from currently undergoing clinical trials in the treatment of abnormal tumor vasculature into the surrounding tissue (1, peritumoral brain edema (PBE). This study preclinically 2). The mechanism(s) of action by which CrA exerts its investigated its potential as an antitumor agent against beneficial effect in the therapy of PBE has not been human brain tumor xenografts. Materials and Methods: The elucidated, but two factors appear to be relevant: decreased in vivo efficacy of CrA as a single agent and in combination vascular leakage and preserved integrity of the endothelial with the antiangiogenic agent, bevacizumab, was examined cells, which ultimately helps to maintain the blood-brain in three different patient-derived human brain tumor barrier (3, 4). xenografts implanted orthotopically (intracranially) or CrA appears to mediate its activity through two subtypes subcutaneously in athymic mice. Results: CrA significantly of G-protein coupled receptors: CRF receptor-1 (CRFR1) increased the lifespan of mice implanted orthotopically with and CRF receptor-2 (CRFR2) (5). These CRFRs are widely two different pediatric brain tumor xenograft models.
    [Show full text]
  • Prescription Drug List
    Your 2017 Prescription Drug List Effective January 1, 2017 Oxford Connecticut Traditional Three-Tier Please read: This document contains information about commonly prescribed medications. This Prescription Drug List (PDL) is accurate as of August 1, 2016 and is subject to change after this date. The next anticipated update will be in January 2017. Your estimated coverage and copay/co-insurance may vary based on the benefit plan you choose and the effective date of the plan. For more information: Call us at the toll-free phone number on your health plan ID card. TTY users can dial 711. Si usted necesita ayuda en español llame al número de teléfono en su tarjeta de identificación, 1- 800-303-6719, 1-888-201-4746. Visit oxfordhealth.com, click on the Pharmacies & Prescriptions tab and then “Online Pharmacy” to log in to the OptumRx1 website and: • Locate a participating retail pharmacy by ZIP code. • Look up possible lower-cost medication alternatives. • Compare medication pricing and options. 1OptumRx is the administrator of your Oxford pharmacy benefit plan. Note: Diabetic supplies and prescription medications may be subject to different cost-share arrangements. Specialized non-standard infant formulas and nutritional supplements may be subject to prior authorization. Please see your Summary of Benefits and Coverage (SBC) for specifics. 1 Your Prescription Drug List This Prescription Drug List (PDL) outlines covered medications and organizes them into cost levels, also known as tiers. An important part of the PDL is giving you choices so you and your doctor can choose the best course of treatment for you. Go to oxfordhealth.com for drug information.
    [Show full text]
  • BRS Pharmacology
    Pharmacology Gary C. Rosenfeld, Ph.D. Professor Department of Integrated Biology and Pharmacology and Graduate School of Biomedical Sciences Assistant Dean for Education Programs University of Texas Medical School at Houston Houston, Texas David S. Loose, Ph.D. Associate Professor Department of Integrated Biology and Pharmacology and Graduate School of Biomedical Sciences University of Texas Medical School at Houston Houston, Texas With special contributions by Medina Kushen, M.D. William Beaumont Hospital Royal Oak, Michigan Todd A. Swanson, M.D., Ph.D. William Beaumont Hospital Royal Oak, Michigan Acquisitions Editor: Charles W. Mitchell Product Manager: Stacey L. Sebring Marketing Manager: Jennifer Kuklinski Production Editor: Paula Williams Copyright C 2010 Lippincott Williams & Wilkins 351 West Camden Street Baltimore, Maryland 21201-2436 USA 530 Walnut Street Philadelphia, PA 19106 All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner. The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care which should not be construed as specific instructions for individual patients. Manufacturers’ product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions. Printed in the United States of America Library of Congress Cataloging-in-Publication Data Rosenfeld, Gary C. Pharmacology / Gary C. Rosenfeld, David S. Loose ; with special contributions by Medina Kushen, Todd A.
    [Show full text]
  • BCBSVT Specialty Drug List Effective 2021.07.01.Xlsx
    Effective Date: 07/01/2021 SPECIALTY DRUG LIST Revised Date: 05/07/2021 DOSAGE EXCLUDED ON NATIONAL DRUG CLASS DRUG NAME GENERIC NAME FORM PERFORMANCE FORMULARY ANEMIA ARANESP SOLN DARBEPOETIN ALFA SOLN INJ ANEMIA ARANESP SOSY DARBEPOETIN ALFA SOLN PREFILLED SYRINGE ANEMIA EPOGEN SOLN EPOETIN ALFA INJ X ANEMIA PROCRIT SOLN EPOETIN ALFA INJ X ANEMIA REBLOZYL SOLR LUSPATERCEPT-AAMT FOR SUBCUTANEOUS INJ ANEMIA RETACRIT SOLN EPOETIN ALFA-EPBX INJ ANTI-GOUT AGENT KRYSTEXXA SOLN PEGLOTICASE INJ (FOR IV INFUSION) ANTI-INFECTIVE PREVYMIS SOLN LETERMOVIR IV SOLN ANTI-INFECTIVE PREVYMIS TABS LETERMOVIR TAB ASTHMA CINQAIR SOLN RESLIZUMAB IV INFUSION SOLN ASTHMA FASENRA SOSY BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE ASTHMA FASENRA PEN SOAJ BENRALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR ASTHMA NUCALA SOAJ MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR ASTHMA NUCALA SOLR MEPOLIZUMAB FOR INJ ASTHMA NUCALA SOSY MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE ASTHMA XOLAIR SOLR OMALIZUMAB FOR INJ ASTHMA XOLAIR SOSY OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE CARDIOVASCULAR VYNDAMAX CAPS TAFAMIDIS CAP CARDIOVASCULAR VYNDAQEL CAPS TAFAMIDIS MEGLUMINE (CARDIAC) CAP CENTRAL NERVOUS SYSTEM AGENTS AUSTEDO TABS DEUTETRABENAZINE TAB CENTRAL NERVOUS SYSTEM AGENTS ENSPRYNG SOSY SATRALIZUMAB-MWGE SUBCUTANEOUS SOLN PREF SYRINGE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ CAPS TASIMELTEON CAPSULE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ LQ SUSP TASIMELTEON ORAL SUSP CHEMOTHERAPY PROTECTANT AMIFOSTINE SOLR AMIFOSTINE CRYSTALLINE FOR INJ CHEMOTHERAPY PROTECTANT ELITEK
    [Show full text]
  • Preferred Drug List (Formulary)
    January 2020 Molina Healthcare of Michigan Preferred Drug List (Formulary) 1 Molina Healthcare of Michigan Preferred Drug List (Formulary) (01/01/2020) INTRODUCTION ..........................................................................................................................................................................................................................................5 PREFACE .....................................................................................................................................................................................................................................................5 PHARMACY AND THERAPEUTICS (P&T) COMMITTEE ..........................................................................................................................................................................5 DRUG LIST PRODUCT DESCRIPTIONS ...................................................................................................................................................................................................5 GENERIC SUBSTITUTION ..........................................................................................................................................................................................................................5 PLAN DESIGN .............................................................................................................................................................................................................................................6
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • 2018 Formulary Drug List
    2018 Formulary Drug List For Federal Employees Health Benefits Program Employees GlobalHealth, Inc. 701 NE 10th Street, Suite 300 Oklahoma City, OK 73104-5403 MFEHBDF18 Lists Updated 12/2017 www.GlobalHealth.com/fehb HELPFUL NUMBERS Plan Issuer: Medication Prior Authorizations: GlobalHealth, Inc. [email protected] PO Box 2393 918.878.7361 Oklahoma City, OK 73101-2393 Mail Claims to: GlobalHealth Customer Care, Language Magellan Rx Management, LLC Assistance, and Disease Management: PO Box 85042 [email protected] Richmond, VA 23261-5042 405.280.2989 (local) 1.877.280.2989 (toll-free) Mail Order Pharmacy: 711 (TTY) Magellan Rx Management, LLC Monday – Friday, 9 a.m. – 5 p.m. Central 1.800.424.1789 (toll-free) www.GlobalHealth.com/fehb 711 (TTY) P.O. Box 620968 Behavioral Health and Substance Use: Orlando, FL 32862 [email protected] 405.280.2989 (local) 24/7 Nurse Help Line: 1.877.280.2989 (toll-free) Information Line 711 (TTY) 1.877.280.2993 (toll-free) Monday – Friday, 9 a.m. – 5 p.m. Central www.GlobalHealth.com/fehb GlobalHealth Compliance Officer: 1.877.280.5852 (toll-free) Pharmacy Benefits Manager: 405.280.5852 Magellan Rx Management, LLC [email protected] Customer Service 1.800.424.1789 (toll-free) GlobalHealth Privacy Officer: 711 (TTY) 405.280.5524 [email protected] i IMPORTANT INFORMATION This formulary applies to Members who enrolled through the Federal Employees Health Benefits Program. Member Materials Your Member materials are three booklets. Each one has a different purpose. These documents are important legal documents. Keep them in a safe place. Booklet Purpose FEHB Brochure Tells you about your benefits.
    [Show full text]
  • September 2017 ~ Resource #330909
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− September 2017 ~ Resource #330909 Medications Stored in the Refrigerator (Information below comes from current U.S. and Canadian product labeling and is current as of date of publication) Proper medication storage is important to ensure medication shelf life until the manufacturer expiration date and to reduce waste. Many meds are recommended to be stored at controlled-room temperature. However, several meds require storage in the refrigerator or freezer to ensure stability. See our toolbox, Medication Storage: Maintaining the Cold Chain, for helpful storage tips and other resources. Though most meds requiring storage at temperatures colder than room temperature should be stored in the refrigerator, expect to see a few meds require storage in the freezer. Some examples of medications requiring frozen storage conditions include: anthrax immune globulin (Anthrasil [U.S. only]), carmustine wafer (Gliadel [U.S. only]), cholera (live) vaccine (Vaxchora), dinoprostone vaginal insert (Cervidil), dinoprostone vaginal suppository (Prostin E2 [U.S.]), varicella vaccine (Varivax [U.S.]; Varivax III [Canada] can be stored in the refrigerator or freezer), zoster vaccine (Zostavax [U.S.]; Zostavax II [Canada] can be stored in the refrigerator or freezer). Use the list below to help identify medications requiring refrigerator storage and become familiar with acceptable temperature excursions from recommended storage conditions. Abbreviations: RT = room temperature Abaloparatide (Tymlos [U.S.]) Aflibercept (Eylea) Amphotericin B (Abelcet, Fungizone) • Once open, may store at RT (68°F to 77°F • May store at RT (77°F [25°C]) for up to Anakinra (Kineret) [20°C to 25°C]) for up to 30 days.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]